Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2B | Q13224 | 6/20 | 0.33 |
| ▸ | GRM5 | P41594 | 4/20 | 0.32 |
| ▸ | DPP4 | P27487 | 3/20 | 0.32 |
| ▸ | MAPT | P10636 | 2/20 | 0.31 |
| ▸ | BRD4 | O60885 | 1/20 | 0.30 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4868740 | 0.91 | GRIN2B (0.41) | GRIN2BGRM5MAPT | |
| SCHEMBL4879016 | 0.90 | KMT2A (0.36) | GRIN2BDPP4BRD4CREBBP | |
| SCHEMBL4872252 | 0.89 | SCN7A (0.35) | GRIN2BGRM5MAPTBRD4CREBBP | |
| SCHEMBL4876586 | 0.88 | KCNH2 (0.34) | GRIN2BGRM5DPP4BRD4CREBBP | |
| SCHEMBL4876599 | 0.87 | DPP4 (0.33) | DPP4MAPT | |
| SCHEMBL4872621 | 0.87 | ALDH1A1 (0.31) | DPP4 | |
| SCHEMBL3938012 | 0.83 | KCNH2 (0.35) | GRIN2BGRM5MAPTBRD4CREBBP | |
| SCHEMBL4877305 | 0.82 | GRIN2B (0.43) | GRIN2BGRM5MAPTGAA | |
| SCHEMBL4868476 | 0.82 | GRIN2B (0.40) | GRIN2BGRM5MAPTGAA | |
| SCHEMBL4868356 | 0.82 | MAPT (0.35) | MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080051384-A1 | ANTIVIRAL AGENTS | GENELABS TECHNOLOGIES, INC. | 2008-02-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080051384-A1 | ANTIVIRAL AGENTS | EIF2AK2, MAVS, ZC3HAV1 | GRIN2B 3420/4885GRM5 4042/4885DPP4 191/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.